• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Advisory Committees

  • Print
  • Share
  • E-mail

Briefing Information for the May 12, 2010 Joint Meeting of the Arthritis Advisory Committee (AAC) and Drug Safety and Risk Management Advisory Committee (DSaRM)

Persons with disabilities having problems accessing the PDF file(s) below may call (301) 796-3634 for assistance.

 

FDA
Disclaimer

Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. § 552).

FDA Briefing Information for the May 12, 2010 Joint Meeting of the Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee (PDF – 1.47MB)

 

 

NicOx S.A.
Disclaimer


The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

NicOx Briefing Information for the May 12, 2010 Joint Meeting of the Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee (PDF – 2.23MB)

Errata to Naproxcinod Advisory Committee Briefing Book (PDF - 260KB)